All In Biotech

Drug Trial Radar · NCT00111722

Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)

A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Tablets for the Treatment of Menstrual Migraine

Last checked: Nov 19, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 393 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

393

Actual

Start

May 27, 2005

Primary completion

Feb 15, 2006

Study completion Feb 23, 2006

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
May 25, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the effectiveness of a marketed drug in the treatment of a menstrual migraine attack.

Conditions

  • Migraine

Interventions

  • MK0462, rizatriptan benzoate / Duration of Treatment -1dayDrug

  • Comparator: placebo / Duration of Treatment - 1 dayDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with 2 hour pain relief: 4-point headache severity scale as recorded in patient diary

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.